Trial Profile
Efficacy and Safety Study of BiRD (Biaxin [Clarithromycin]/Revlimid [Lenalidomide]/Dexamethasone) Combination Therapy in Relapsed/Refractory Myeloma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Clarithromycin (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 08 May 2018 Status changed from recruiting to withdrawn prior to enrolment.
- 12 Dec 2016 New trial record